US 6326507B1
· Gribble et al.
· 2001
[cited by applicant]
US 6552075B2
· Gribble et al.
· 2003
[cited by applicant]
US 6974801B2
· Honda et al.
· 2005
[cited by applicant]
US 7176237B2
· Honda et al.
· 2007
[cited by applicant]
US 7288568B2
· Gribble et al.
· 2007
[cited by applicant]
US 7435755B2
· Konopleva et al.
· 2008
[cited by applicant]
US 7678830B2
· Honda et al.
· 2010
[cited by applicant]
US 7714012B2
· Honda et al.
· 2010
[cited by applicant]
US 7795305B2
· Konopleva et al.
· 2010
[cited by applicant]
US 7863327B2
· Gribble et al.
· 2011
[cited by applicant]
US 7915402B2
· Anderson et al.
· 2011
[cited by applicant]
US 7943778B2
· Jiang et al.
· 2011
[cited by applicant]
US 8034955B2
· Gribble et al.
· 2011
[cited by applicant]
US 8067394B2
· Honda et al.
· 2011
[cited by applicant]
US 8067465B2
· Honda et al.
· 2011
[cited by applicant]
US 8071632B2
· Jiang et al.
· 2011
[cited by applicant]
US 8088824B2
· Walling et al.
· 2012
[cited by applicant]
US 8124656B2
· Anderson et al.
· 2012
[cited by applicant]
US 8124799B2
· Anderson et al.
· 2012
[cited by applicant]
US 8129429B2
· Sporn et al.
· 2012
[cited by applicant]
US 8258329B2
· Anderson et al.
· 2012
[cited by applicant]
US 8299046B2
· Sporn et al.
· 2012
[cited by applicant]
US 8309601B2
· Walling et al.
· 2012
[cited by applicant]
US 8314137B2
· Honda et al.
· 2012
[cited by applicant]
US 8338618B2
· Jiang et al.
· 2012
[cited by applicant]
US 8394967B2
· Jiang et al.
· 2013
[cited by applicant]
US 8440820B2
· Anderson et al.
· 2013
[cited by applicant]
US 8440854B2
· Anderson et al.
· 2013
[cited by applicant]
US 8455544B2
· Sporn et al.
· 2013
[cited by applicant]
US 8513436B2
· Anderson et al.
· 2013
[cited by applicant]
US 8586775B2
· Gribble et al.
· 2013
[cited by applicant]
US RE45288E
· Anderson et al.
· 2014
[cited by applicant]
US 8921340B2
· Sporn et al.
· 2014
[cited by applicant]
US RE45325E
· Anderson et al.
· 2015
[cited by applicant]
US 8993640B2
· Anderson et al.
· 2015
[cited by applicant]
US 9000188B2
· Honda et al.
· 2015
[cited by applicant]
US 9090574B2
· Anderson et al.
· 2015
[cited by applicant]
US 9102681B2
· Anderson et al.
· 2015
[cited by applicant]
US 9174941B2
· Anderson et al.
· 2015
[cited by applicant]
US 9233998B2
· Anderson et al.
· 2016
[cited by applicant]
US 9249089B2
· Jiang et al.
· 2016
[cited by applicant]
US 9278912B2
· Jiang et al.
· 2016
[cited by applicant]
US 9290536B2
· Anderson et al.
· 2016
[cited by applicant]
US 9464082B2
· Donner et al.
· 2016
[cited by applicant]
US 9796668B2
· Anderson et al.
· 2017
[cited by applicant]
US 9884809B2
· Anderson et al.
· 2018
[cited by applicant]
US 20020042535A1
· Gribble et al.
· 2002
[cited by applicant]
US 20020115856A1
· Sakya
· 2002
[cited by applicant]
US 20090048205A1
· Meyer et al.
· 2009
[cited by applicant]
US 20090060873A1
· Sporn et al.
· 2009
[cited by applicant]
US 20130122053A1
· Sporn et al.
· 2013
[cited by applicant]
US 20140088163A1
· Jiang et al.
· 2014
[cited by applicant]
US 20140377235A1
· Sporn et al.
· 2014
[cited by applicant]
US 20150080465A1
· Chin et al.
· 2015
[cited by applicant]
US 20180265455A1
· Anderson et al.
· 2018
[cited by applicant]
US 20200077658A1
· Sambasivan et al.
· 2020
[cited by applicant]
WO WO1999065478
· 1999
[cited by applicant]
WO WO2002047611
· 2002
[cited by applicant]
WO WO2003059339
· 2003
[cited by applicant]
WO WO2004064723
· 2004
[cited by applicant]
WO WO2006089406
· 2006
[cited by applicant]
WO WO2008064132
· 2008
[cited by applicant]
WO WO2008064133
· 2008
[cited by applicant]
WO WO2008136838
· 2008
[cited by applicant]
WO WO2009023232
· 2009
[cited by applicant]
WO WO2009023845
· 2009
[cited by applicant]
WO WO2009089545
· 2009
[cited by applicant]
WO WO2009129545
· 2009
[cited by applicant]
WO WO2009129546
· 2009
[cited by applicant]
WO WO2009129548
· 2009
[cited by applicant]
WO WO2009146216
· 2009
[cited by applicant]
WO WO2009146218
· 2009
[cited by applicant]
WO WO2010011782
· 2010
[cited by applicant]
WO WO2010053817
· 2010
[cited by applicant]
WO WO2010093944
· 2010
[cited by applicant]
WO WO2011130302
· 2011
[cited by applicant]
WO WO2012083306
· 2012
[cited by applicant]
WO WO2012125488
· 2012
[cited by applicant]
WO WO2013163344
· 2013
[cited by applicant]
WO WO2013188818
· 2013
[cited by applicant]
WO WO2014040056
· 2014
[cited by applicant]
WO WO2014040060
· 2014
[cited by applicant]
WO WO2014040073
· 2014
[cited by applicant]
WO WO2015027206
· 2015
[cited by applicant]
WO WO2015112792
· 2015
[cited by applicant]
WO WO2016130927
· 2016
[cited by applicant]
WO WO2019241796
· 2019
[cited by applicant]
WO WO2019246461
· 2019
[cited by applicant]
Abstract of WO 2015112792, 2023.
[cited by examiner]
Albini and Sporn, “Opinion: the tumour microenvironment as a target for chemoprevention,”
[cited by applicant]
Andresen and Margaretha, “Preparation of Dialkyl 2-Cyanocycloalk-2-en-1-ones,”
[cited by applicant]
Caron et al., “Versatile Strategy to access tricycles related to quassinoids and triterpenes,”
[cited by applicant]
Chadalapaka, et al., “Structure-dependent inhibition of bladder and pancreatic cancer cell growth by 2-substituted glycyrrhetinic and ursolic acid derivatives,”
[cited by applicant]
Chintharlapalli et al., “Structure-dependent activity of glycyrrhetinic acid derivatives as peroxisome proliferator-activated receptor γ agonists in colon cancer cells,”
[cited by applicant]
Clinton et al., “Steroidal [3,2-c]pyrazoles. II. Androstanes, 19-norandrostanes and their unsaturated analogs,”
[cited by applicant]
Connolly et al., “Grandiofolione: a novel tetranortriterpenoid,”
[cited by applicant]
De Ruggieri et al., “Deidrogenazione e bromurazione di beta-chetonitrili steroidali,”
[cited by applicant]
Dinkova-Kostova et al., “Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress,”
[cited by applicant]
Duan et al., “Immunosuppressive terpenoids from extracts of
[cited by applicant]
Favaloro et al., “Design and synthesis of tricyclic compounds with enone functionalities in rings A and C: a novel class of highly active inhibitors of nitric oxide production in mouse macrophages,”
[cited by applicant]
Ferreira et al., “Phytochemistry of the mopane,
[cited by applicant]
Finlay et al., “Novel A-ring cleaved analogs of oleanolic and ursolic acids which affect growth regulation in NRP.152 prostate cells,”
[cited by applicant]
Finlay et al., “The Effects of A and C Ring Modification of Oleanolic and Ursolic Acid on the Inhibition of Nitric Oxide Formation in Mouse Macrophages,” 213th American Chemical Society National Meeting, Abstract: 084, …
[cited by applicant]
Hatcher et al., “Curcumin: from ancient medicine to current clinical trials,”
[cited by applicant]
Honda et al., “A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production,”
[cited by applicant]
Honda et al., “An efficient synthesis of tricyclic compounds (+)-(4aβ, 8aβ, 10aα)-1,2,3,4,4a,6,7,8,8a,9,10,10a-Dodecahydro-1,1,4a-Trimethyl-2-Oxophenanthrene-8a-Carboxolic acid, its methyl ester, and (+)-(4aβ,8aβ,10aα)-…
[cited by applicant]
Honda et al., “Design and synthesis of 23, 24-dinoroleanolic acid derivatives, novel triterpenoid-steroid hybrid molecules,”
[cited by applicant]
Honda et al., “Design and synthesis of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages,”
[cited by applicant]
Honda et al., “Design, synthesis, and biological evaluation of biotin conjugates of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid for the isolation of the protein targets,”
[cited by applicant]
Honda et al., “Efficient synthesis of (−)- and (+)-tricyclic compounds with enome functionalities in rings A and C. A novel class of orally active anti-inflammatory and cancer chemopreventive agents,”
[cited by applicant]
Honda et al., “New enone derivatives of oleanolic acid and ursolic acid as inhibitors of nitric oxide production in mouse macrophages,”
[cited by applicant]
Honda et al., “New synthetic oleanane and ursane triterpenoids as inhibitors of nitric oxide production in mouse macrophages,” The Fifth Chemical Congress of North America, Cancun, Mexico, Abstract 552 and slides for or…
[cited by applicant]
Honda et al., “Novel synthetic oleanane and ursane triterpenoids with various enone functionalities in ring A as inhibitors of nitric oxide production in mouse macrophages,”
[cited by applicant]
Honda et al., “Novel synthetic oleanane triterpenoids: a series of highly active inhibitors of nitric oxide production in mouse macrophages,”
[cited by applicant]
Honda et al., “Novel tricyclic compounds having acetylene groups at C-8a and cyano enones in rings A and C: highly potent anti-inflammatory and cytoprotective agents,”
[cited by applicant]
Honda et al., “Revision and confirmation of the regiochemistry of isoxazoles derived from methyl oleanonate and lanost-8-en-3-one. Synthesis of a new lanostane triterpenoid with a cyano-enone functionality in ring A,”
[cited by applicant]
Honda et al., “Synthesis of (±)-3,3-ethylenedioxy-14α-hydroxy-5-picrasene-11,16-dione, a 14αH-picrasane derivative,”
[cited by applicant]
Honda et al., “Synthesis of a novel dicyano abietane analogue: a potential antiinflammatory agent,”
[cited by applicant]
Honda et al., “Synthetic oleanane and ursane triterpenoids with modified rings A and C: A series of highly active inhibitors of nitric oxide production in mouse macrophages, ”
[cited by applicant]
Honda et al., “Tricyclic Compounds Containing Nonenolizable Cyano Enones. A Novel Class of Highly Potent Anti-Inflammatory and Cytoprotective Agents,”
[cited by applicant]
Huerta et al., “Characterization of novel small-molecule NRF2 activators: Structural and biochemical validation of stereospecific KEAP1 binding”,
[cited by applicant]
Hybertson, et al., “Oxidative stress in health and disease: The therapeutic potential of Nrf2 activation”,
[cited by applicant]
International Preliminary Report on Patentability issued in corresponding PCT Application No. PCT/US2015/012579, mailed on Jul. 26, 2016.
[cited by applicant]
International Preliminary Report on Patentability issued in corresponding PCT Application No. PCT/US2017/000094, mailed on Jun. 27, 2019.
[cited by applicant]
International Preliminary Report on Patentability issued in corresponding PCT Application No. PCT/US2016/017769, mailed on Aug. 15, 2017.
[cited by applicant]
International Preliminary Report on Patentability issued in corresponding PCT Application No. PCT/US2011/065897, mailed on Jun. 27, 2013.
[cited by applicant]
International Search Report and Written Opinion issued in corresponding PCT Application No. PCT/US2015/012579, mailed on Mar. 19, 2015.
[cited by applicant]
International Search Report and Written Opinion issued in corresponding PCT Application No. PCT/US2017/000094, mailed on Mar. 26, 2018.
[cited by applicant]
International Search Report and Written Opinion issued in corresponding PCT Application No. PCT/US2016/017769, mailed on Apr. 15, 2016.
[cited by applicant]
International Search Report and Written Opinion issued in corresponding PCT Application No. PCT/US2011/065897, mailed on Jul. 27, 2012.
[cited by applicant]
Kato, Research Flow of Optical Heterogeneous Drugs, Yakuji, Yakuji Jihou, Limited, 29(10):2039-42, 1987.
[cited by applicant]
Kato, Research Flow of Optical Heterogeneous Drugs, Yakuji, Yakuji Jihou, Limited, 29(10):2039-42, 1987. (Partial English Translation).
[cited by applicant]
Kincl et al., “Pituitary gonadotropin inhibitory action of neutral steroids,”
[cited by applicant]
Kobayashi et al., “The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds,”
[cited by applicant]
Konopleva et al., “Activation of nuclear transcription factor PPARγ by the novel triterpenoid CDDO as targeted therapy in breast cancer,” 2002 Keystone Symposium, Abstract No. 539, 2002.
[cited by applicant]
Konopleva et al., “Mechanisms and Activity of PPARγ-Active Triterpenoids CDDO and CDDO-Me in Leukemias,”
[cited by applicant]
Konopleva et al., “Novel synthetic triterpenoid CDDO-Me: potent antiproliferative, proapoptotic and differentiating agent in AML,”
[cited by applicant]
Konopleva et al., “Novel synthetic triterpenoid, CDDO, and its methyl ester: Potent antiproliferative, proapoptotic and differentiating agents in AML,”
[cited by applicant]
Konopleva et al., “Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia,”
[cited by applicant]
Konopleva et al., “Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias,”
[cited by applicant]
Konopleva et al., “PPARγ Ligand CDDO Induces Apoptosis in Leukemias Via Multiple Apoptosis Pathways,” Abstracts of the 44th Annual Meeting of the American Society of Hematology, Abstract No. 2209, 2002.
[cited by applicant]
Konopleva et al., “PPARγ Ligands Are Potent Inducers of Apoptosis in Leukemias and Lymphomas,” American Society of Hematology 43rd Annual Meeting and Exposition, Abstract No. 501, 2001.
[cited by applicant]
Konopleva et al., “PPARγ Nuclear Receptor as a Novel Molecular Target in Leukemia Therapy,”
[cited by applicant]
Konopleva et al., “PPARγ nuclear receptor as a novel therapeutic target in AML,”
[cited by applicant]
Konopleva et al., “PPARγ nuclear receptor as a novel therapeutic target in AML,”
[cited by applicant]
Konopleva et al., “Suppression of ERK Activation is Required for Triterpenoid Methyl-CDDO-Induced Apoptosis in AML,”
[cited by applicant]
Konopleva et al., “Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells,”
[cited by applicant]
Konopleva et al., “Synthetic triterpenoid CDDO as a novel therapy for resistant breast cancer,”
[cited by applicant]
Konopleva et al., “The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells,”
[cited by applicant]
Konopleva et al., “The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia,”
[cited by applicant]
Liby et al., “A novel acetylenic tricyclic bis-(cyano enone) potently induces phase 2 cytoprotective pathways and blocks liver carcinogenesis induced by aflatoxin,”
[cited by applicant]
Liby et al., “Novel semisynthetic analogues of betulinic acid with diverse cytoprotective, antiproliferative, and proapoptotic activities,”
[cited by applicant]
Liby et al., “The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis,”
[cited by applicant]
Liby et al., “The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells,”
[cited by applicant]
Liby et al., “The synthetic triterpenoids CDDO-Methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice,”
[cited by applicant]
Liby et al., “The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling,”
[cited by applicant]
Liby et al., “Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer,”
[cited by applicant]
Nohira, Optically Active Substance, Organic Industrial Chemistry thereof, Asakura Shoten Co., Ltd., 20-21, 1989.
[cited by applicant]
Nohira, Optically Active Substance, Organic Industrial Chemistry thereof, Asakura Shoten Co., Ltd., 20-21, 1989. (Partial English Translation).
[cited by applicant]
Orr et al., “Steroids. CCLXV. Studies in cyano steroids. 3. Unsaturated 2-cyano steroids,”
[cited by applicant]
Ribo et al., “Synthesis of methyl 1,11-dioxooleanan-2,12-dien-30-oate and its 24-nor derivative,”
[cited by applicant]
Satoh et al., “Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophilic phase II inducers,”
[cited by applicant]
Shin et al., “Inhibitory roles of NRF2 and an oleanolic triterpenoid on adipocyte differentiation and obesity,” dissertation submitted to John Hopkins University in conformity with the requirements for the degree of Doc…
[cited by applicant]
Shin et al., “NRF2 modulates aryl hydrocarbon receptor signaling: influence on adipogenesis,”
[cited by applicant]
Soufli et al., “Overview of cytokines and nitric oxide involvement in immuno-pathogenesis of inflammatory bowel diseases”,
[cited by applicant]
Sporn et al., “New Synthetic Triterpenoids: Potent Agents for Prevention and Treatment of Tissue Injury Caused by Inflammatory and Oxidative Stress,”
[cited by applicant]
Subba Rao, et al., “Chemical modifications of natural triterpenes—glycyrrhetinic and boswellic acids: evaluation of their biological activity,”
[cited by applicant]
Suh et al., “A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO), induces cell differentiation in human myeloid leukemias,” Proceedings of the American Association for Cancer Res…
[cited by applicant]
Suh et al., “A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity,”
[cited by applicant]
Suh et al., “New triterpenoids as cancer preventive and anti-inflammatory agents,” Proceedings of the American Association for Cancer Research, Abstract No. 1457, 38: 216, 1997.
[cited by applicant]
Suh et al., “Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages,”
[cited by applicant]
Suh et al., “Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2),” Proceedings of the American Association for Cancer Research Annual Meeting, 39: Abstract No. 1821, …
[cited by applicant]
Suh et al., “Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL,”
[cited by applicant]
Suh et al., “Synthetic triterpenoids enhance transforming growth factor β/Smad signaling,”
[cited by applicant]
Suh et al., “Triterpenoids CDDO and CDDO-Me Down-Regulate FLIP Expression and Sensitize AML Cells to Trail-Induced Apoptosis,” American Society of Hematology 43rd Annual Meeting and Exposition, Abstract No. 498, 2001.
[cited by applicant]
Sun et al., “Structure-activity relationships of oleanan- and ursane-type triterpenoids,” Botanical Studies, 47:339-368, 2006.
[cited by applicant]
Xu et al., “The role of nitric oxide in cancer”,
[cited by applicant]
Yamanaka et al., Quarterly Chemical Review, Separation of Optically Isomers, Academic Society Publishing Center, Inc., 6:8-10, 124, 212-213, 1999.
[cited by applicant]
Yamanaka et al., Quarterly Chemical Review, Separation of Optically Isomers, Academic Society Publishing Center, Inc., 6:8-10, 124, 212-213, 1999. (Partial English Translation).
[cited by applicant]
Yates et al., “Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-, 12-dioxooleana-1,9(11)-dien-28-oyl]imidazole,”
[cited by applicant]
You et al., “Synthesis and cytotoxic activity of a-ring modified betulinic acid derivatives,”
[cited by applicant]